Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

H2AX phosphorylation level in peripheral blood mononuclear cells as an event-free survival predictor for bladder cancer.

Turinetto V, Pardini B, Allione A, Fiorito G, Viberti C, Guarrera S, Russo A, Anglesio S, Ruo Redda MG, Casetta G, Cucchiarale G, Destefanis P, Oderda M, Gontero P, Rolle L, Frea B, Vineis P, Sacerdote C, Giachino C, Matullo G.

Mol Carcinog. 2016 Nov;55(11):1833-1842. doi: 10.1002/mc.22431. Epub 2015 Nov 19.

2.

Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer.

Russo A, Modica F, Guarrera S, Fiorito G, Pardini B, Viberti C, Allione A, Critelli R, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Frea B, Vineis P, Sacerdote C, Matullo G.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2439-46. doi: 10.1158/1055-9965.EPI-14-0228. Epub 2014 Sep 18.

3.

The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcome.

Racioppi M, Salmaso L, Brombin C, Arboretti R, D'Agostino D, Colombo R, Serretta V, Brausi M, Casetta G, Gontero P, Hurle R, Tenaglia R, Altieri V, Bartoletti R, Maffezzini M, Siracusano S, Morgia G, Bassi PF.

Urol Int. 2015;94(3):262-9. doi: 10.1159/000365292. Epub 2014 Aug 27.

PMID:
25171377
4.

Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?

Gontero P, Gillo A, Fiorito C, Oderda M, Pacchioni D, Casetta G, Peraldo F, Zitella A, Tizzani A, Ricceri F.

Urol Int. 2014;92(2):136-42. doi: 10.1159/000351961. Epub 2013 Sep 25.

PMID:
24080613
5.

Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy.

Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, Critelli R, Russo A, Andrew AS, Ye Y, Wu X, Kiemeney LA, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Vineis P, Matullo G.

Int J Cancer. 2013 Oct 15;133(8):2004-9. doi: 10.1002/ijc.28186. Epub 2013 Apr 25.

6.

125I brachytherapy for localized prostate cancer: a single institution experience.

Guarneri A, Botticella A, Filippi AR, Munoz F, Beltramo G, Casetta G, Giglioli FR, Tizzani A, Ragona R, Ricardi U.

Tumori. 2013 Jan-Feb;99(1):83-7. doi: 10.1700/1248.13793.

PMID:
23549005
7.

Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study.

Oderda M, Ricceri F, Pisano F, Fiorito C, Gurioli A, Casetta G, Zitella A, Pacchioni D, Gontero P.

Urol Int. 2013;90(2):184-90. doi: 10.1159/000343431. Epub 2013 Jan 17.

PMID:
23328160
8.

Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma.

Guarneri A, Botticella A, Ragona R, Filippi AR, Munoz F, Casetta G, Gontero P, Tizzani A, Ricardi U.

World J Urol. 2013 Apr;31(2):411-5. doi: 10.1007/s00345-012-0932-z. Epub 2012 Aug 26.

PMID:
22922810
9.

ERCC1 haplotypes modify bladder cancer risk: a case-control study.

Ricceri F, Guarrera S, Sacerdote C, Polidoro S, Allione A, Fontana D, Destefanis P, Tizzani A, Casetta G, Cucchiarale G, Vineis P, Matullo G.

DNA Repair (Amst). 2010 Feb 4;9(2):191-200. doi: 10.1016/j.dnarep.2009.12.002. Epub 2010 Jan 12.

PMID:
20061190
10.

Intake of fruits and vegetables and polymorphisms in DNA repair genes in bladder cancer.

Sacerdote C, Matullo G, Polidoro S, Gamberini S, Piazza A, Karagas MR, Rolle L, De Stefanis P, Casetta G, Morabito F, Vineis P, Guarrera S.

Mutagenesis. 2007 Jul;22(4):281-5. Epub 2007 May 21.

PMID:
17515441
11.

Myxoid renal tumor with myoepithelial differentiation mimicking a salivary gland pleomorphic adenoma: description of a case.

Pacchioni D, Volante M, Casetta G, Sapino A, Marchiò C, Bussolati G.

Am J Surg Pathol. 2007 Apr;31(4):632-6.

PMID:
17414112
12.

[Adenocarcinoma of the scrotum: a case report].

Ghignone GP, Petraz M, Casetta G, Greco A, Zitella A, Fiorio M, Buffa Di Perrero E, Tizzani A.

Minerva Urol Nefrol. 2006 Sep;58(3):173-4. Italian. No abstract available.

PMID:
17124489
13.

Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.

Zitella A, Berruti A, Destefanis P, Mengozzi G, Torta M, Ceruti C, Casetta G, Mosca A, Greco A, Rolle L, Aimo G, Aroasio E, Tizzani A, Dogliotti L, Fontana D; Gruppo Oncologico Urologico Piemontese (GOUP).

Clin Chim Acta. 2007 Feb;377(1-2):103-7. Epub 2006 Sep 5.

PMID:
17034778
14.

Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study.

Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S, Karagas M, Casetta G, Rolle L, Piazza A, Vineis P.

Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2569-78.

15.

Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.

Bollito ER, Pacchioni D, Lopez-Beltran A, Volante M, Terrone C, Casetta G, Mari M, DePompa R, Cappia S, Papotti M.

Anal Quant Cytol Histol. 2005 Aug;27(4):218-24.

PMID:
16220833
16.

Prostatic duct carcinoma with combined prostatic duct adenocarcinoma and urothelial carcinoma features: report of a case.

Pacchioni D, Casetta G, Piovano M, Fraire F, Volante M, Sapino A, Tizzani A, Bussolati G.

Int J Surg Pathol. 2004 Jul;12(3):293-7.

PMID:
15306945
17.

Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).

Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, Frea B, Tizzani A.

Eur Urol. 2004 Sep;46(3):339-43.

PMID:
15306105
18.

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer.

Albrecht W, Van Poppel H, Horenblas S, Mickisch G, Horwich A, Serretta V, Casetta G, Maréchal JM, Jones WG, Kalman S, Sylvester R.

Br J Cancer. 2004 Jan 12;90(1):100-5.

19.

Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly.

Bo M, Ventura M, Marinello R, Capello S, Casetta G, Fabris F.

Crit Rev Oncol Hematol. 2003 Sep;47(3):207-11.

20.

Clear cell sarcoma of the kidney with invasion of the inferior vena cava.

Rosso D, Ghignone GP, Bernardi D, Zitella A, Casetta G, De Zan A, Tizzani A.

Urol Int. 2003;70(3):251-2. Review.

PMID:
12660471
21.

Immunohistochemical evaluation of the safety of transurethral electrovaporization of the prostate and its clinical results.

Tizzani A, Gontero P, Casetta G, Piana P, Baima C, De Zan A, Bodo G, Pacchioni D.

Prostate Cancer Prostatic Dis. 1999 Jan;2(1):16-20.

22.

Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies.

Airoldi L, Orsi F, Magagnotti C, Coda R, Randone D, Casetta G, Peluso M, Hautefeuille A, Malaveille C, Vineis P.

Carcinogenesis. 2002 May;23(5):861-6.

PMID:
12016161
23.

[Communication between urologist and pathologist. Proposal for the standardization of histological tests requests for neoplasms].

Casetta G, Moiso A, Zitella A, Tizzani A.

Minerva Urol Nefrol. 2001 Dec;53(4):221-9. Italian.

PMID:
11753250
24.

Progression from superficial to invasive carcinoma of the bladder: genetic evidence of either clonal heterogeneous events.

Volante M, Tizzani A, Casetta G, Zitella A, Pacchioni D, Bussolati G.

Hum Pathol. 2001 May;32(5):468-74.

PMID:
11381363
25.

Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer.

Priolo G, Gontero P, Martinasso G, Mengozzi G, Formiconi A, Pelucelli G, Zitella A, Casetta G, Viberti L, Aimo G, Tizzani A.

Clin Chim Acta. 2001 Mar;305(1-2):47-53.

PMID:
11249922
26.

Bladder pheochromocytoma: a 3-year follow-up after transurethral resection (TURB).

Baima C, Casetta G, Vella R, Tizzani A.

Urol Int. 2000;65(3):176-8.

PMID:
11054040
27.

BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.

Casetta G, Gontero P, Zitella A, Pelucelli G, Formiconi A, Priolo G, Martinasso G, Mengozzi G, Aimo G, Viberti L, Tizzani A.

Urol Int. 2000;65(2):100-5.

PMID:
11025432
28.

Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.

Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C, Muir GH, Tizzani A.

Eur Urol. 2000 Sep;38(3):287-96.

PMID:
10940702
29.

Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.

Sier CF, Casetta G, Verheijen JH, Tizzani A, Agape V, Kos J, Blasi F, Hanemaaijer R.

Clin Cancer Res. 2000 Jun;6(6):2333-40.

30.

[Rare renal tumors (neoplasms other than conventional renal cell carcinoma). Clinico-pathologic aspects and review of the literature].

Casetta G, De Zan A, Moiso A, Zitella A, Viberti L, Tizzani A.

Minerva Urol Nefrol. 1999 Sep;51(3):149-56. Italian.

PMID:
10638178
31.

[Screening for prostate cancer: reasons for, reasons against].

Tizzani A, Casetta G, Gontero P.

Minerva Urol Nefrol. 1999 Sep;51(3):137-41. Italian. No abstract available.

PMID:
10638176
32.

Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance.

Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brünner N, Blasi F.

Lab Invest. 1999 Jun;79(6):717-22.

PMID:
10378514
33.

Recurrent calcium oxalate urolithiasis in a man with familial periodic paralysis and hypokalemia.

Zitella A, Moiso A, De Zan A, Casetta G, Piana P, Tizzani A.

J Urol. 1999 Jun;161(6):1899. No abstract available.

PMID:
10332462
34.

Circadian antidiuretic hormone variation in elderly men complaining of persistent nocturia after urinary flow obstruction removal.

Bodo G, Gontero P, Casetta G, Alpa M, Brossa G, Russo R, Tizzani A.

Scand J Urol Nephrol. 1998 Sep;32(5):320-4.

PMID:
9825393
35.

White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study.

Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, Giacomelli G, Terrone C, Casetta G, Vineis P.

Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):341-6.

36.
37.

DNA flow cytometry and 67Ki proliferating index as prognostic factors of early recurrence and progression in G1-G2/Ta-T1 and G3/Ta-T1 transitional cell carcinoma of the bladder.

Tizzani A, Casetta G, Gontero P, Giammò A, Ghabin H, Demurtas S, Pacchioni D.

Minerva Urol Nefrol. 1997 Sep;49(3):141-3.

PMID:
9396221
38.

Tobacco smoke, recurrences, and p53/bcl-2 expression in bladder cancer.

Pacchioni D, Martone T, Ghisolfi G, Bussolati G, Tizzani A, Casetta G, Vineis P.

Carcinogenesis. 1997 Aug;18(8):1659-61.

PMID:
9276645
39.

[Perirenal immunoblastic lymphoma. Description of a case].

Casetta G, Giammò A, Moiso A, Pacchioni D.

Minerva Urol Nefrol. 1997 Jun;49(2):99-101. Italian.

PMID:
9281084
40.

p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.

Casetta G, Gontero P, Russo R, Pacchioni D, Tizzani A.

Eur Urol. 1997;32(2):229-36.

PMID:
9286659
41.

[Renal agenesis and homolateral seminal vesicle cyst. Case report].

Casetta G, Bodo G, Gamba P, Ghabin H, Ferraris C, De Zan A.

Minerva Urol Nefrol. 1996 Dec;48(4):189-91. Italian.

PMID:
9005586
42.

[Surgical treatment of benign prostatic hypertrophy and Kelami syndrome].

Bodo G, Casetta G, Piana P, Ghabin H, Gamba P, Tizzani A.

Minerva Urol Nefrol. 1995 Jun;47(2):81-3. Italian.

PMID:
8560354
43.

[Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].

Casetta G, Gamba P, Piana P, Pecchio F, Tizzani A.

Minerva Urol Nefrol. 1995 Mar;47(1):9-12. Italian.

PMID:
7570264
44.

[A new method for treating benign prostatic hypertrophy: transurethral prostatic vaporization].

Tizzani A, De Zan A, Bodo G, Casetta G.

Minerva Urol Nefrol. 1995 Mar;47(1):53-4. Italian. No abstract available.

PMID:
7570263
45.

[Appearance in 2 brothers of double primary neoplasms: right renal carcinoma and gastric adenocarcinoma].

Casetta G, Piana P, Gamba P, Gontero P, Bodo G, Lauro D, Calderini P.

Minerva Urol Nefrol. 1995 Mar;47(1):49-51. Review. Italian.

PMID:
7570261
46.

[Leiomyosarcoma of the spermatic cord. Case report and revision of the literature].

Bodo G, Casetta G, Ghabin H, Vottero M, Gamba P.

Minerva Urol Nefrol. 1994 Sep;46(3):179-81. Review. Italian.

PMID:
7801216
47.

Carcinogen-DNA adducts in bladder biopsies and urothelial cells: a risk assessment exercise.

Talaska G, Schamer M, Casetta G, Tizzani A, Vineis P.

Cancer Lett. 1994 Aug 29;84(1):93-7.

PMID:
8076366
48.

[The use of hemorrhage occluder pins in radical pelvic urologic surgery].

De Zan A, Bodo G, Gamba P, Casetta G, Squintone L, Vottero M.

Minerva Urol Nefrol. 1993 Sep;45(3):123-4. Italian.

PMID:
8278879
49.
50.

Immunohistochemical detection of estrogen and progesterone receptors in the normal urinary bladder and in pseudomembranous trigonitis.

Pacchioni D, Revelli A, Casetta G, Cassoni P, Piana P, Tizzani A, Bussolati G, Massobrio M.

J Endocrinol Invest. 1992 Nov;15(10):719-25.

PMID:
1491120

Supplemental Content

Loading ...
Support Center